“Over two decades of AF catheter ablation have brought great advances to our field. Nevertheless, operator efficiency and procedure efficacy remain the key obstacles in our strive to grow and to serve our patients better,” Professor Karl-Heinz Kuck
AF recurs in up to 50% of patients post-ablation, mostly due to PV reconnection. Measuring lesion permanency during ablation procedures enables the electrophysiologist to improve outcome.
Our solution addresses key needs in the high-growth $3 billion EP market
Inventor of CARTO and co-founder of Biosense (now Biosense-Webster, part of Johnson & Johnson), the market leader in the cardiac navigation and arrhythmia ablation market
“As a customer-centric company, EPD’s mission is to solve the most significant unmet needs and challenges of electrophysiologists today” ‒ Chief Medical Director, EPD R&D subsidiary, Dr. Yitzhack Schwartz